acetylsalicylic acid sodium salt

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: acetylsalicylic acid sodium salt
• 英文别名: sodium acetylsalicylate；Sodium;3-acetyl-2-hydroxybenzoate
• 化学式: C₉H₇O₄*Na
• 分子量: 202.142
• InChiKey: VNPSRVHVUXZPTN-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.04
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  77.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  acetylsalicylic acid sodium salt 、 CuCl2 dihydrate 、 阿司匹林 生成 sodium O-acetylsalicylate
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Compositions and methods for inhibition of phospholipase a2 mediated inflammation
  申请人：Dennis Edward

  公开号：US20050148549A1

  公开（公告）日：2005-07-07

  Specific, highly potent 2-oxo-amide based inhibitors of phospholipase A 2 (PLA 2 ) activity are provided. A role for PLA 2 activity in spinally mediated inflammatory processes is established, and a method for treating hyperalgesia and other inflammatory conditions associated with PLA 2 activity is provided.

  提供了基于2-氧代酰胺的特异性、高效的磷脂酶A2（PLA2）活性抑制剂。已经确定了PLA2活性在脊髓介导的炎症过程中的作用，并提供了一种用于治疗与PLA2活性相关的高痛感和其他炎症病症的方法。
• Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
  申请人：——

  公开号：US20030119794A1

  公开（公告）日：2003-06-26

  The present invention is directed to novel pharmaceutical combinations including compositions and kits comprising bretylium as the active ingredient, as well as methods for preventing and/or treating conditions related to the cardiovascular system using such novel pharmaceutical combinations.

  本发明涉及包括布雷替琳作为活性成分的新型药物组合物和套装，以及利用这种新型药物组合物预防和/或治疗与心血管系统相关的疾病的方法。
• Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0024690A1

  公开（公告）日：1981-03-11

  A composition consisting essentially of nalbuphine and acetylsalicyclic acid, derivative or salt thereof, gives unexpectedly enhanced analgetic activity.

  一种主要由纳布啡和乙酰水杨酸、其衍生物或盐组成的组合物意外地增强了镇痛活性。
• Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis
  申请人：van der Kraaij, Antonius Marinus Maria

  公开号：EP0669132A1

  公开（公告）日：1995-08-30

  The current invention involves a new treatment for human atherosclerosis. It concerns primary as well as secondary prevention of atherosclerosis by a pharmaceutical composition of vitamin E and acetylsalicylate. The development of atherosclerosis is suppressed at three different levels using this particular composition : 1) reduction of oxidation of LDL, in vivo, by vitamin E, 2) stabilization of endothelial cellmembranes by vitamin E making these cells less vulnerable to oxidation and 3) the anti-platelet action of acetylsalicylate which prevents platelet aggregation, thrombus formation and cytokines release which decreases inflammatory reactions and smooth-muscle-cell proliferation. An accidental advantage of the composition is the relatively small amount of acetylsalicylate that is needed when combined with vitamin E. This is quite important in view of the dose-dependent side-effects of acetylsalicylate. For these reasons, the composition can be expected to be effective and safe. It can be used widely against atherosclerosis and should be considered an additional weapon against atherosclerosis along with the reduction of known riskfactors such as hypertension, smoking, hypercholesterolemia and diabetes mellitus. The composition is designed to treat and/or prevent diseases arising from atherosclerosis such as angina pectoris, myocardial infarction, transient ischemic attacks, stroke and claudicatio intermittens.

  本发明涉及一种治疗人体动脉粥样硬化的新方法。它涉及通过维生素 E 和乙酰水杨酸的药物组合物对动脉粥样硬化进行一级和二级预防。使用这种特殊的组合物可以在三个不同的层面上抑制动脉粥样硬化的发展：1）维生素 E 减少体内低密度脂蛋白的氧化；2）维生素 E 稳定内皮细胞膜，使这些细胞不易被氧化；3）乙酰水杨酸抗血小板作用，防止血小板聚集、血栓形成和细胞因子的释放，从而减少炎症反应和平滑肌细胞的增殖。鉴于乙酰水杨酸的副作用与剂量有关，这一点非常重要。基于这些原因，我们可以预期这种成分既有效又安全。它可广泛用于防治动脉粥样硬化，并应被视为在减少高血压、吸烟、高胆固醇血症和糖尿病等已知危险因素的同时，防治动脉粥样硬化的额外武器。该成分旨在治疗和/或预防动脉粥样硬化引起的疾病，如心绞痛、心肌梗塞、短暂性脑缺血发作、中风和间歇性跛行。
• TWO-COMPONENT COMPOSITIONS COMPRISING ACETYL SALICYLIC ACID AND A CARBONATE SALT
  申请人：Asamedic AS

  公开号：EP3501523A1

  公开（公告）日：2019-06-26

  The present invention relates to a novel two-component composition comprising acetylsalicylic acid (ASA) and a salt of carbonic acid which is particularly useful in providing an aqueous solution of ASA for immediate peroral administration.

  本发明涉及一种由乙酰水杨酸（ASA）和一种碳酸盐组成的新型双组分组合物，该组合物特别适用于提供可立即口服的 ASA 水溶液。